Indian Pharma industry moving towards formulations

Indian Pharma industry is slowing moving up the value chain. Earlier it used to manufacture active pharmaceutical ingredient at low cost compared to world. Now with competition from China, which provides API at 15-20% low cost, it makes sense to shift focus elsewhere. Many top companies like Lupin, Novartis, Ranbaxy have less revenue stream from API than from formulations. There could also be the reason that formulation business has grown faster than APIs for some companies. API is low scale commodity with low margin. Moreover, with a large number of patent expiries in developed markets like the US and Europe, Indian companies, with skills to develop and manufacture low-cost generic drugs, see a much more lucrative opportunity there than utilising their capacities for manufacturing APIs.
Read More

  • No Image
    Piramal Enterprises Ltd

    Piramal Enterprises Ltd is part of the Ajay Piramal group of companies with presence in Healthcare, Financial Services and Information Management sectors across 100 countries an

  • No Image
    Plant Lipids Pvt Ltd

    Plant Lipids Pvt Ltd is engaged in the manufacture of spice oleoresins since 1979 and is one of the largest exporters from India. The top 10 customers constitute ~30 per cent of

  • No Image
    Plethico Pharmaceuticals Ltd

    Plethico Pharmaceuticals Limited is a leading global healthcare / pharmaceutical company with a strong emphasis on the herbal and nutraceuticals segments.

    The company wh

  • No Image
    Prans Life Science

    Prans Life Science is involved in trading, marketing, and export of a wide range of pharmaceutical formulations, APIs, and intermediate. Their products include rosuvastatin calc